Somatostatin pp 157-167 | Cite as

Somatostatin and Behavior: Preclinical and Clinical Studies

  • Charles B. Nemeroff
  • Thomas J. Walsh
  • Garth Bissette
Part of the Serono Symposia, USA book series (SERONOSYMP)


Since the discovery of the chemical identity of the hypothalamic hypophysiotropic hormones, considerable research has been conducted on their physiologic role in regulating the secretion of the adenohypophyseal hormones.


Passive Avoidance Neuropsychiatric Disorder Senile Dementia Postmortem Brain Tissue Passive Avoidance Behavior 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reichlin S. Somatostatin (first of two parts). N Engl J Med 1983; 309: 1495.PubMedCrossRefGoogle Scholar
  2. 2.
    Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983; 309: 1556.PubMedCrossRefGoogle Scholar
  3. 3.
    Brownstein MJ, Palkovits M, Saavedra JM, Bassiri RM, Utiger RD. Thyrotropin-releasing hormone in specific nuclei of the rat brain. Science 1974; 185: 267.PubMedCrossRefGoogle Scholar
  4. 4.
    Chappell P, Smith MA, Kilts CD, et al. Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci (in press).Google Scholar
  5. 5.
    Krisch B, Leonhardt H. An intermittent somatostatin-immunoreactivity in the cortex and basal ganglia of the rat. Cell Tissue Res 1980; 205: 327.PubMedGoogle Scholar
  6. 6.
    Hokfelt T, Efendic S, Hellerstrom C, Johansson 0, Luft R, Arimura A. Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special references to the A5 cells of the pancreatic islets and to the hypothalamus. Acta Endocrinol 1975; 80 (suppl 200): 1.Google Scholar
  7. 7.
    Dorn A, Bernstein H-G, Hahn H-J, Kostmann G. Occurrence of somatostatin-like immunoreactivity (SLI) in the dorsal hippocampus of the sand rat (Psammomys obesus). Acta Histochem 1979; 65: 276.PubMedCrossRefGoogle Scholar
  8. 8.
    Krisch B. Differing immunoreactivities of somatostatin in the cortex and the hypothalamus of the rat. Cell Tissue Res 1980; 212: 457.PubMedGoogle Scholar
  9. 9.
    Dalsgaard C-J, Hokfelt T, Johansson 0, Elde R. Somatostatin immunoreactive cell bodie in the dorsal horn and the parasympathetic intermediolateral nucleus of the rat spinal cord. Neurosci Lett 1981; 27: 336.CrossRefGoogle Scholar
  10. 10.
    Lechen RM, Goodman RH, Rosenblatt M, Reichlin S, Habener JF. Prosomatostatin-specific antigen in rat brain: localization by immunocytochemical staining with an antiserum to an antiserum to a synthetic sequence of prepro-somatostatin. Proc Natl Acad Sci USA 1983; 80: 2780.Google Scholar
  11. 11.
    Brownstein M, Arimiva A, Sato H, Kizer JS. The regional distribution of somatostatin in rat brain. Brain Res 1977; 126: 584–8.CrossRefGoogle Scholar
  12. 12.
    Epelbaum J, Tapia-Arancibia L, Kordon C, Ottesen OP, Ben-Ari Y. Regional distribution of somatostatin within the amygdaloid complex of the rat brain. Brain Res 1979; 174: 172.PubMedCrossRefGoogle Scholar
  13. 13.
    Kobayashi RM, Brown MR, Vale W. Regional distribution of neurotensin and somatostatin in rat brain. Endocrinology 1975; 96 (6): 1456–61.CrossRefGoogle Scholar
  14. 14.
    Yamada T, Marshak D, Basinger S, Walsh J, Morley J, Stell W. Somatostatin-like immunoreactivity in the retina. Proc Natl Acad Sci USA 1980; 77: 1691.PubMedCrossRefGoogle Scholar
  15. 15.
    Geola FL, Yamada T, Warwick RJ, Tourtelotte WW, Hershman JM. Regional distribution of somatostatin-like immunoreactivity in the human brain. Brain Res 1981; 229: 35.PubMedCrossRefGoogle Scholar
  16. 16.
    Epelbaum J, Brazeau P, Tsang D, Brawer J, Martin JB. Subcellular distribution of radioimmunoassayable somatostatin in rat brain. Brain Res 1977; 126: 309.PubMedCrossRefGoogle Scholar
  17. 17.
    Iversen LL, Iversen SD, Bloom F, Douglas C, Brown M, Vale W. Calcium-dependent release of somatostatin and neurotensin from rat brain in vitro. Nature 1978; 273: 161.Google Scholar
  18. 18.
    Delfs J, Robbins R, Connolly JL, Dichter M, Reichlin S. Somatostatin production by rat cerebral neurones in dissociated cell culture. Nature 1980; 283: 676.PubMedCrossRefGoogle Scholar
  19. 19.
    Srikant CB, Patel YC. Somatostatin receptors: identification and characterization in rat brain membranes. Proc Natl Acad Sci 1981; 78: 3930.PubMedCrossRefGoogle Scholar
  20. 20.
    Reubi JC, Rivier J, Perrin M, Brown M, Vale W. High affinity binding sites for a somatostatin-28 analog in rat brain. Life Sci 1981; 28: 1049.CrossRefGoogle Scholar
  21. 21.
    Segal DS, Mandell AJ. Differential behavioral effects of hypothalamic polypeptides. In: Prange AJ Jr, ed. The thyroid, drugs and behavior. New York: Raven Press, 1974.Google Scholar
  22. 22.
    Cohn ML, Cohn M. ‘Barrel rotation’ induced by somatostatin in the non-lesioned rat. Brain Res 1975; 96: 138.PubMedCrossRefGoogle Scholar
  23. 23.
    Havlicek V, Rezek M, Friesen H. Somatostatin and thyrotropin-releasing hormone: central effect on sleep and motor system. Pharmacol Biochem Behav 1976; 4: 455.PubMedCrossRefGoogle Scholar
  24. 24.
    Rezek M, Havlicek V, Hughes KR, Friesen H. Cortical administration of somatostatin (SRIF): effect on sleep and motor behavior. Pharmacol Biochem Behav 1976; 5: 73.PubMedCrossRefGoogle Scholar
  25. 25.
    Rezek M, Havlicek V, Hughes KR, Friesen H. Central site of action of somatostatin (SRIF): role of hippocampus. Neuropharmacology 1976; 15: 499.PubMedCrossRefGoogle Scholar
  26. 26.
    Rezek M, Havlicek V, Leybin L, et al. Neostriatal administration of somatostatin: differential effect of small and large doses on behavior and motor control. Can J Physiol Pharmacol 1977; 55: 234.PubMedCrossRefGoogle Scholar
  27. 27.
    Rezek M, Havlicek V, Hughes KR, Friesen H. Behavioral and motor excitation and inhibition induced by the administration of small and large doses of somatostatin into the amygdala. Neuropharmacology 1977; 16: 157.PubMedCrossRefGoogle Scholar
  28. 28.
    Gordin A, Ericksson L, Blom AK, Taskinen MR, Fyhrquist F. Lack of behavioral effects following intraventricular infusion of somatostatin in the conscious goat. Pharmacol Biochem Behav 1978; 9: 255.PubMedCrossRefGoogle Scholar
  29. 29.
    Vecsei L, Schwarzberg H, Telegdy G. The effect of somatostatin on the self-stimulation of rats. Neuroendocrinol Lett 1982; 4: 37.Google Scholar
  30. 30.
    Vecsei L, Bollok I, Telegdy G. Intracerebroventricular somatostatin attenuates electroconvulsive shock-induced amnesia in rats. Peptides 1983; 4: 293.PubMedCrossRefGoogle Scholar
  31. 31.
    Vecsei L, Bollok L, Penke B, Telegdy G. Somatostatin and (D-Trp8, D-Cys14)-somatostatin delay extinction and reverse electroconvulsive shock-induced amnesia in rats. Psychoneuroendocrinology 1986; 11: 111.PubMedCrossRefGoogle Scholar
  32. 32.
    Szabo S, Reichlin S. Somatostatin in cat tissues is depleted by cysteamine administration. Endocrinology 1981; 109: 2255.Google Scholar
  33. 33.
    Brown MR, Fisher LA, Sawchenko PE, Swanson LW, Vale WW. Biological effects of cysteamine: relationship to somatostatin depletion. Regul Pept 1983; 5: 163.PubMedCrossRefGoogle Scholar
  34. 34.
    Beal MF, Martin JB. Depletion of striatal somatostatin by local cysteamine injection. Brain Res 1984; 308: 319.PubMedCrossRefGoogle Scholar
  35. 35.
    Nemeroff CB, Konkol RJ, Bissette G, et al. Analysis of the disruption in hypothalamic-pituitary regulation in rats treated neonatally with monosodium L-glutamate (MSG): evidence for the involvement of tuberoinfundibular cholinergic and dopaminergic systems in neuro-endocrine regulation. Endocrinology 1977; 101: 613.PubMedCrossRefGoogle Scholar
  36. 36.
    Nemeroff CB, Youngblood WW, Manberg PJ, Prange AJ Jr, Kizer JS. Regional brain concentration of neuropeptides in Huntington’s chorea and schizophrenia. Science 1983; 221: 972.PubMedCrossRefGoogle Scholar
  37. 37.
    Tan AT, Tsay D, Renaud LP, Martin JB. Effect of somatostatin on calcium transport in guinea pig cortex synaptosomes. Brain Res 1977; 123: 193.PubMedCrossRefGoogle Scholar
  38. 38.
    Gothert M. Somatostatin selectively inhibits noradrenaline release from hypothalamic neurons. Nature 1980; 287: 86.CrossRefGoogle Scholar
  39. 39.
    Garcia-Sevilla JA, Magnusson T, Carlsson A. Effect of intracerebroventricularly administered somatostatin on brain monoamine turnover. Brain Res 1978; 155: 159.PubMedCrossRefGoogle Scholar
  40. 40.
    Catalan RE, Aragones MD, Martinez AM. Somatostatin effect on cyclic AMP and cyclic GMP levels in rat brain. Biochim Biophys Acta 1979; 586: 213.CrossRefGoogle Scholar
  41. 41.
    Renaud LP, Martin JB, Brazeau P. Depressant action of TRH, LH-RH and somatostatin on activity of central neurons. Nature 1975; 255: 233.PubMedCrossRefGoogle Scholar
  42. 42.
    Ioffe S, Havlicek V, Friesen H, Chernick V. Effect of somatostatin (SRIF) and L-glutamate on neurons of the sensorimotor cortex in awake habituated rabbits. Brain Res 1978; 153: 414.PubMedCrossRefGoogle Scholar
  43. 43.
    Dodd J, Kelly JS. Is somatostatin an excitatory transmitter in the hippocampus? Nature 1978; 273: 674.PubMedCrossRefGoogle Scholar
  44. 44.
    Olpe H-R, Balcar VJ, Bittiger H, Rink H, Sieber P. Central actions of somatostatin. Eur J Pharmacol 1980; 63: 127.PubMedCrossRefGoogle Scholar
  45. 45.
    Nemeroff CB, Bissette G. Neuropeptides in psychiatric disorders. In: Berger PA, Brodie HKH, eds. American handbook of psychiatry (vol 8). Basic Books, 1986.Google Scholar
  46. 46.
    Cain ST, Nemeroff CB. Neuropeptides and neurotransmitters in Alzheimer’s disease. In: Busse EW, Maddox GL, eds. Advances in gerontology and geriatrics. 13th Congress of the Intranational Association of Gerontology. New York: Springer (in press).Google Scholar
  47. 47.
    Davies P, Katzman R, Terry RD. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer’s disease and Alzheimer senile dementia. Nature 1980; 288: 279.PubMedCrossRefGoogle Scholar
  48. 48.
    Davies P, Terry RD. Cortical somatostatin-like immunoreactivity in cases of Alzheimer’s disease and senile dementia of the Alzheimer’s type. Neurobiol Aging 1981; 2: 9.PubMedCrossRefGoogle Scholar
  49. 49.
    Nemeroff CB, Bissette G, Busby WH Jr, et al. Regional brain concentrations of neurotensin, thyrotropin-releasing hormone and somatostatin in Alzheimer’s disease. Soc Neurosci Abst 1983; 9: 1052.Google Scholar
  50. 50.
    Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci Lett 1980; 20: 373.PubMedCrossRefGoogle Scholar
  51. 51.
    Rossor M, Emson P, Dawbarn D, Dockray G, Mountjoy C, Roth M. Postmortem studies in peptides in Alzheimer’s disease and Huntington’s disease. In: Martin JB, Barchas JD, eds. Neuropeptides in neurologic and psychiatric disease. New York: Raven Press, 1986.Google Scholar
  52. 52.
    Ferrier IN, Cross AJ, Johnson JA, et al. Neuropeptides in Alzheimer’s type dementia. J Neurol Sci 1983; 62: 159.PubMedCrossRefGoogle Scholar
  53. 53.
    Arai H, Moroji T, Kosaka T. Somatostatin and vasoactive intestinal peptide in post-mortem brains from patients with Alzheimer’s type dementia. Neurosci Lett 1984; 52: 73.PubMedCrossRefGoogle Scholar
  54. 54.
    Beal MF, Uhl G, Mazierek N, Rowell N, Martin JB. Somatostatin: alterations in the central nervous system in neurological diseases. In: Martin JB, Barchas JD, eds. Neuropeptides in neurologic and psychiatric disease. New York: Raven Press, 1986.Google Scholar
  55. 55.
    Candy JM, Gascoigne AD, Biggins JA, et al. Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer’s disease. J Neurol Sci 1985; 71: 315.PubMedCrossRefGoogle Scholar
  56. 56.
    Epelbaum J, Ruberg M, Mouse E, Javoy-Agid F, Dubois B, Agid Y. Somatostatin and dementia in Parkinson’s disease. Brain Res 1983; 278: 376.PubMedCrossRefGoogle Scholar
  57. 57.
    Delfs JR, Zhu CH, Dichter MA. Coexistence of acetylcholinesterase and somatostatin-immunoreactivity in neurons cultured from rat cerebrum. Science 1984; 223 (4631): 61–3.PubMedCrossRefGoogle Scholar
  58. 58.
    Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NPV. Reduced lumbar CSF somatostatin levels in Alzheimer’s senile dementia. Life Sci 1982; 31: 2073.Google Scholar
  59. 59.
    Oram JJ, Edwardson J, Millard PH. Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia. Gerontol 1981; 27: 216.CrossRefGoogle Scholar
  60. 60.
    Serby M, Richardson SB, Twente S, Siekierski J, Rotrosen J. Somatostatin in Alzheimer’s disease. Neurobiol Aging 1984; 5: 187.PubMedCrossRefGoogle Scholar
  61. 61.
    Beal MF, Growdon JH, Mazurek MF, Martin JB. CSF somatostatin-like immunoreactivity in dementia. Neurology 1986; 36: 294.PubMedCrossRefGoogle Scholar
  62. 62.
    Raskind MA, Peskink ER, Lampe JH, Risse SC, Taborsky GJ, Dorsa D. Cerebrospinal fluid vasopressin oxytocin, somatostatin, and 6-endorphin in Alzheimer’s disease. Arch Gen Psychiatry 1986; 43: 382.PubMedCrossRefGoogle Scholar
  63. 63.
    Bissette G, Widerlov E, Walleus H, et al. Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in neuropsychiatric disorders. Arch Gen Psychiatry (in press).Google Scholar
  64. 64.
    Karlsson I, Widerlov E, Melin EV, et al. Changes of CSF neuropeptides after environmental stimulation in dementia. Nordic Psychiat J 1985; 39 (suppl 11): 75.CrossRefGoogle Scholar
  65. 65.
    Dupont E, Christensen SE, Hansen AP, Olivarias BF, Orskov H. Low cerebrospinal fluid somatostatin in Parkinson’s disease: an irreversible abnormality. Neurology 1982; 32: 312.PubMedCrossRefGoogle Scholar
  66. 66.
    Cramer H, Kohler J, Oeper G, Schonberg G, Schroter E. Huntington’s chorea-measurements of somatostatin substance P and cyclic nucleotides in the cerebrospinal fluid. J Neurol 1981; 225: 183.PubMedCrossRefGoogle Scholar
  67. 67.
    Gerner RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 1982; 238: 298.PubMedCrossRefGoogle Scholar
  68. 68.
    Rubinow DR, Gold PW, Post RM, et al. CSF somatostatin in affective illness. Arch Gen Psychiatry 1983; 40: 409.PubMedCrossRefGoogle Scholar
  69. 69.
    Doran AR, Rubinow DR, Roy A, Pickar D. CSF somatostatin and abnormal responses to dexamethasone administration in schizophrenic and depressed patients. Arch Gen Psychiatry 1986; 43: 365.PubMedCrossRefGoogle Scholar
  70. 70.
    Aronin N, Cooper PE, Lorenz LJ, et al. Somatostatin is increased in the basal ganglia in Huntington’s disease. Ann Neurol 1983; 13: 519.PubMedCrossRefGoogle Scholar
  71. 71.
    Beal MF, Bird ED, Langlais PJ, Martin JB. Somatostatin is increased in the nucleus accumbers in Huntington’s disease. Neurology 1984; 34: 663.PubMedCrossRefGoogle Scholar
  72. 72.
    Marshall PE, Landis DMD. Huntington’s disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes. Brain Res 1985; 329: 71.PubMedCrossRefGoogle Scholar
  73. 73.
    Beal MF, Benoit R, Bird ED, Martin JB. Somatostatin 28 (1–12) immunoreactivity is increased in Huntington’s disease. Neurosci Lett 1985; 56: 377.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Charles B. Nemeroff
    • 1
    • 2
  • Thomas J. Walsh
    • 3
  • Garth Bissette
    • 1
  1. 1.Departments of PsychiatryDuke University Medical CenterDurhamUSA
  2. 2.Departments of PharmacologyDuke University Medical CenterDurhamUSA
  3. 3.Biological Sciences Research CenterUniversity of North Carolina School of MedicineChapel HillUSA

Personalised recommendations